Zacks Investment Research on MSN6d
Alnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
which is developing ALN-APP in collaboration with Regeneron for both Alzheimer’s and related condition cerebral amyloid angiopathy (CAA), which can cause haemorrhaging in the brain. Eisai and ...
After hours: March 19 at 6:06:16 PM EDT Loading Chart for ALNY ...
After hours: March 7 at 5:54:08 p.m. EST Loading Chart for ALNY ...
Persistence of effort in apathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback